Merck KGaA Signs an Exclusive Worldwide License Agreement with Day One for Pimasertib and MSC2015103B
Merck KGaA Signs an Exclusive Worldwide License Agreement with Day One for Pimasertib and MSC2015103B
Shots:
- Merck KGaA to receive up front, additional regulatory, approval, and sales milestone along with royalties on sales of pimasertib and MSC2015103B. The agreement broadens Day One’s clinical-stage pipeline of targeted cancer therapies with the additions of MEK inhibitors
- Day One plans to initiate a P-I/II study to evaluate the safety, tolerability, and preliminary efficacy of pimasertib in combination with DAY101 in patients aged ≥12yrs. with advanced solid tumors with MAPK inhibitors
- Pimasertib and MSC2015103B are oral, highly-selective MEK I/II inhibitors. Pimasertib has been studied in 10+ P-I/II studies in ~900 patients with various tumor types
Click here to read full press release/ article | Ref: Businesswire | Image: Coworking Centrum